Rivory LP - Search Results

1

Factors affecting cytochrome P-450 3A activity in cancer patients.

Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A. Baker SD, et al. Among authors: rivory lp. Clin Cancer Res. 2004 Dec 15;10(24):8341-50. doi: 10.1158/1078-0432.CCR-04-1371. Clin Cancer Res. 2004. PMID: 15623611

2

Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.

Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Charles KA, et al. Among authors: rivory lp. Clin Cancer Res. 2006 Dec 15;12(24):7492-7. doi: 10.1158/1078-0432.CCR-06-0023. Clin Cancer Res. 2006. PMID: 17189422

3

Optimizing the erythromycin breath test for use in cancer patients.

Rivory LP, Slaviero K, Seale JP, Hoskins JM, Boyer M, Beale PJ, Millward MJ, Bishop JF, Clarke SJ. Rivory LP, et al. Clin Cancer Res. 2000 Sep;6(9):3480-5. Clin Cancer Res. 2000. PMID: 10999732 Clinical Trial.

4

Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response.

Rivory LP, Slaviero KA, Clarke SJ. Rivory LP, et al. Br J Cancer. 2002 Jul 29;87(3):277-80. doi: 10.1038/sj.bjc.6600448. Br J Cancer. 2002. PMID: 12177794 Free PMC article.

5

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.

Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, Clarke SJ. Sharma R, et al. Among authors: rivory lp. Clin Cancer Res. 2008 Feb 1;14(3):817-25. doi: 10.1158/1078-0432.CCR-07-0425. Clin Cancer Res. 2008. PMID: 18245544

6

Clinical pharmacokinetics of docetaxel.

Clarke SJ, Rivory LP. Clarke SJ, et al. Among authors: rivory lp. Clin Pharmacokinet. 1999 Feb;36(2):99-114. doi: 10.2165/00003088-199936020-00002. Clin Pharmacokinet. 1999. PMID: 10092957 Review.

7

The erythromycin breath test for the prediction of drug clearance.

Rivory LP, Slaviero KA, Hoskins JM, Clarke SJ. Rivory LP, et al. Clin Pharmacokinet. 2001;40(3):151-8. doi: 10.2165/00003088-200140030-00001. Clin Pharmacokinet. 2001. PMID: 11327195 Review.

8

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.

Li KM, Rivory LP, Clarke SJ. Li KM, et al. Among authors: rivory lp. Br J Cancer. 2007 Oct 22;97(8):1071-6. doi: 10.1038/sj.bjc.6603995. Epub 2007 Oct 2. Br J Cancer. 2007. PMID: 17912246 Free PMC article. Clinical Trial.

9

Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy.

Slaviero KA, Read JA, Clarke SJ, Rivory LP. Slaviero KA, et al. Among authors: rivory lp. Nutr Cancer. 2003;46(2):148-57. doi: 10.1207/S15327914NC4602_07. Nutr Cancer. 2003. PMID: 14690790

10

Predicting the toxicity of weekly docetaxel in advanced cancer.

Charles KA, Rivory LP, Stockler MR, Beale P, Beith J, Boyer M, Clarke SJ. Charles KA, et al. Among authors: rivory lp. Clin Pharmacokinet. 2006;45(6):611-22. doi: 10.2165/00003088-200645060-00004. Clin Pharmacokinet. 2006. PMID: 16719542 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters